What is the administration route for Monjarou, a potential medication, in a patient with an unknown medical history and condition?

Administration of Mounjaro (Tirzepatide)

Mounjaro (tirzepatide) is administered as a once-weekly subcutaneous injection, available in single-dose prefilled pens and single-dose vials. 1

Route and Formulation

• Subcutaneous injection is the only approved route of administration for tirzepatide 1
• The medication comes in two formulations:
  • Single-dose prefilled pens (most common for patient self-administration) 1
  • Single-dose vials 1

Dosing Schedule

• Once-weekly administration is the standard dosing frequency 1
• Tirzepatide is used as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus 1, 2

Mechanism and Clinical Context

• Tirzepatide is a first-in-class dual incretin agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors 1, 2
• It can be used as monotherapy or as add-on therapy to oral glucose-lowering medications and insulin 1

Important Safety Considerations

• The most common adverse events are gastrointestinal (nausea, diarrhea, decreased appetite, vomiting), typically mild to moderate in severity 1
• There is a low risk of clinically significant or severe hypoglycemia 1
• One case report has documented pulmonary embolism following tirzepatide initiation, though the relationship remains unclear and requires further investigation 3